Category

Archives

Blog of Signaling Pathways

CDK4/6 inhibitor enhances the radiosensitization of esophageal squamous cell carcinoma (ESCC) by activating autophagy signaling via the suppression of mTOR

109 views | Apr 17 2022

Wen-Jun Qin et al. found that palbociclib improved the radiosensitivity of ESCC in vivo and in vitro, and thus it might be a promising radiosensitization agent for the treatment of ESCC. [Read the Full Post]

Improved Survival With Enzalutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer

121 views | Apr 16 2022

Andrew J Armstrong et al.found that enzalutamide plus ADT significantly prolongs survival versus placebo plus ADT in patients with mHSPC. [Read the Full Post]

Erythrocyte-cancer Hybrid Membrane-camouflaged Mesoporous Silica Nanoparticles Loaded with Gboxin for Glioma-targeting Therapy

165 views | Apr 15 2022

Xiuxiu Jiao et al. found that the (MSNs/Gboxin)@[RBC-U] exhibited significant anti-cancer effected in vitro and the specific self-recognition to GBM cells. [Read the Full Post]

An effective AKT inhibitor-PARP inhibitor combination therapy for recurrent ovarian cancer

151 views | Apr 15 2022

Jing Xu et al. suggested that the combination of AKT inhibitor and PARP inhibitor could be a viable approach for clinical testing in recurrent ovarian cancer patients. [Read the Full Post]

High expression level of ROR1 and ROR1-signaling associates with venetoclax resistance in chronic lymphocytic leukemia

167 views | Apr 15 2022

Emanuela M Ghia et al. found that Wnt5a-induced ROR1-signaling can enhance resistance to venetoclax therapy. [Read the Full Post]

Multiple myeloma: Combination therapy of BET proteolysis targeting chimeric molecule with CDK9 inhibitor

0 views | Apr 14 2022

Su-Lin Lim et al. found that the combination of a BET PROTAC (ARV 825) plus AZD 4573 (CDK9 inhibitor) was effective against MM cells. [Read the Full Post]

Update on International Medical Taxonomies of Biomarkers and Their Applications in Management of Thyroid Cancers

113 views | Apr 14 2022

Maria Trovato thought that BM taxonomies should have common standards internationally recognized. [Read the Full Post]

B7-H4 expression is upregulated by PKCδ activation and contributes to PKCδ-induced cell motility in colorectal cancer

209 views | Apr 13 2022

Bin Zhou et al. found that B7-H4 expression was upregulated by STAT3 activation via PKCδ and played roles in PKCδ-induced cancer cell motility and metastasis, suggesting that the PKCδ/STAT3/B7-H4 axis might be a potential therapeutic target for CRC. [Read the Full Post]

Effect of Maternal Docosahexaenoic Acid Supplementation on Very Preterm Infant Growth: Secondary Outcome of a Randomized Clinical Trial

179 views | Apr 13 2022

Georgina Angoa et al. showed that DHA positively affected female infants' neonatal weight profile and velocity and negatively affected male infants' weight at 36 weeks' PMA. [Read the Full Post]

Cotargeting of Bcl-2 and Mcl-1 shows promising antileukemic activity against AML cells including those with acquired cytarabine resistance

66 views | Apr 12 2022

Fangbing Liu et al. revealed that the combined inhibition of Mcl-1 and Bcl-2 showed promise against AML cells, including relapse/refractory AML. [Read the Full Post]

Degradation and inhibition of epigenetic regulatory protein BRD4 exacerbate Alzheimer's disease-related neuropathology in cell models

94 views | Apr 12 2022

Siyi Zhang et al. not only showed that BRD4 was a novel epigenetic component that regulated BACE1 and Aβ levels, but also provided novel and translational insighted into the targeting of BRD4 for potential clinical applications. [Read the Full Post]

Pharmacological Depletion of Microglia Leads to a Dose-Dependent Reduction in Inflammation and Senescence in the Aged Murine Brain

59 views | Apr 11 2022

Milan R Stojiljkovic et al. found that increased and detrimental brain inflammation in aged murine brain could be impaired by selectively reducing the microglial cell population. [Read the Full Post]

Unmasking BCL-2 Addiction in Synovial Sarcoma by Overcoming Low NOXA

89 views | Apr 11 2022

Carter K Fairchild Jr et al. found remarkably depressed levels of the endogenous MCL-1 inhibitor, NOXA, in SS compared to other sarcomas. [Read the Full Post]

GRP78 blockade overcomes intrinsic resistance to UBA1 inhibitor TAK-243 in glioblastoma

153 views | Apr 10 2022

Xu Zhang et al. provided a new strategy for improving the sensitivity of GBM to TAK-243 treatment and experimental basis for further clinical trials to evaluate this combination therapy. [Read the Full Post]

Neddylation is essential for β-catenin degradation in Wnt signaling pathway

160 views | Apr 10 2022

Bojun Wang et al. highlighted the importance of reassessing previously identified ubiquitylation substrates. [Read the Full Post]

Case Report: Intraocular Hemorrhage in a Primary Vitreoretinal Lymphoma Patient Treated With Zanubrutinib

29 views | Apr 09 2022

Xiao Zhang found that Bleeding is a major concern in the use of zanubrutinib. It is suggested that drugs be held for a few days prior to procedures and surgeries. [Read the Full Post]

Zanubrutinib monotherapy in relapsed/refractory indolent non-Hodgkin lymphoma

41 views | Apr 09 2022

Tycel Phillips found that a favorable benefit-risk profile and support zanubrutinib as a potentially meaningful addition to available therapies for patients with relapsed/refractory MZL and FL. This study is registered on [Read the Full Post]

Inhibition of Bromodomain and Extra Terminal (BET) Domain Activity Modulates the IL-23R/IL-17 Axis and Suppresses Acute Graft- Versus-Host Disease

67 views | Apr 08 2022

Katiri J Snyder et al. identified a role for BET proteins in regulating the IL-23R/STAT3/IL-17 pathway. [Read the Full Post]

Dynamic transcriptome analysis reveals signatures of paradoxical effect of vemurafenib on human dermal fibroblasts

92 views | Apr 07 2022

Eyleen Corrales et al. found the relevance of evaluating the effected of the drugs on non-transformed stromal components, carefully considering the implications of their administration either as mono- or combination therapies. [Read the Full Post]

The p300 inhibitor A-485 exerts antitumor activity in growth hormone pituitary adenoma

110 views | Apr 07 2022

Chenxing Ji et al. found that inhibition of HAT p300 by its selective inhibitor A-485 was a promising therapy for GHPA. [Read the Full Post]